Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
S. W. Quist, A. J. Postma, K. J. Myrén, L. A. de Jong, M. J. Postma
| Year of publication: |
2023
|
|---|---|
| Authors: | Quist, S. W. ; Postma, A. J. ; Myrén, K. J. ; de Jong, L. A. ; Postma, M. J. |
| Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 24.2023, 9, p. 1455-1472
|
| Subject: | Cost–benefit analysis | C5-inhibitors | Costs and cost analysis | Eculizumab | Hemoglobinuria | Paroxysmal | Ravulizumab | Niederlande | Netherlands | Kosten-Nutzen-Analyse | Cost-benefit analysis | Kostenanalyse | Cost analysis | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Gesundheitskosten | Health care costs |
freely available
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-022-01556-5 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10014427311